Home › Funds › ALETHEA CAPITAL MANAGEMENT, LLC › RNA
ALETHEA CAPITAL MANAGEMENT, LLC position in RNA
ATRIUM THERAPEUTICS INC · Health Care
ALETHEA CAPITAL MANAGEMENT, LLC reported holding 43,758 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$362K, representing 0.18% of its reported portfolio and ranking #31 among its reported holdings. ALETHEA CAPITAL MANAGEMENT, LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ALETHEA CAPITAL MANAGEMENT, LLC's RNA position evolved
ALETHEA CAPITAL MANAGEMENT, LLC first disclosed a stake in RNA in Q1 2026 at 43,758 shares (US$585K). The position peaked in Q2 2026 at 43,758 shares, worth US$589K. Across 3 filings, ALETHEA CAPITAL MANAGEMENT, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 43,758 shares valued at US$362K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 43.76K | $585.04K | New |
| Q2 2026 | 43.76K | $588.54K | Hold |
| Q3 2026 | 43.76K | $362.32K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNA and 13F data
RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 98 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), TIG Advisors, LLC (US$7.6M), Slotnik Capital, LLC (US$3.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RNA
- Sessa Capital IM, L.P. 1.50M sh · $20.18M · Q2 2026
- TIG Advisors, LLC 561.53K sh · $7.55M · Q2 2026
- Slotnik Capital, LLC 237.64K sh · $3.20M · Q2 2026
- Arbiter Partners Capital Management LLC 311.72K sh · $2.58M · Q3 2026
- NEXPOINT ASSET MANAGEMENT, L.P. 150.03K sh · $2.02M · Q2 2026
- Bracebridge Capital, LLC 139.24K sh · $1.87M · Q2 2026
- Marble Bar Asset Management LLP 103.85K sh · $1.40M · Q2 2026
- Kalehua Capital Management LLC 112.65K sh · $932.76K · Q3 2026
- Athos Capital Ltd 107.97K sh · $894.00K · Q3 2026
- Trium Capital LLP 58.38K sh · $483.40K · Q3 2026
- Twin Securities, Inc. 26.52K sh · $356.65K · Q2 2026
More on ALETHEA CAPITAL MANAGEMENT, LLC
FAQ
How long has ALETHEA CAPITAL MANAGEMENT, LLC held RNA?
ALETHEA CAPITAL MANAGEMENT, LLC has disclosed RNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is ALETHEA CAPITAL MANAGEMENT, LLC's current position in RNA?
As of Q3 2026, ALETHEA CAPITAL MANAGEMENT, LLC holds 43.76K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $362.32K, representing 0.18% of its reported portfolio and ranking #31.
Has ALETHEA CAPITAL MANAGEMENT, LLC been buying or selling RNA?
In the latest 13F filing (Q3 2026), ALETHEA CAPITAL MANAGEMENT, LLC held unchanged its position in RNA. The position peaked in Q2 2026 at 43.76K shares.
Which other funds hold RNA?
Other major institutional holders of RNA include Sessa Capital IM, L.P., TIG Advisors, LLC, Slotnik Capital, LLC, among 98 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.